Jean‐Jacques Grob
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Dermatology top 0.05%
Papers in
- Oncology 224
- Cancer Immunotherapy and Biomarkers 104
- CAR-T cell therapy research 97
- Cutaneous Melanoma Detection and Management 84
-
- Melanoma and MAPK Pathways 109
- Co-authors
- Caroline Robert (79 shared papers)Dirk Schadendorf (70 shared papers)Georgina V. Long (72 shared papers)Claus Garbe (33 shared papers)James Larkin (55 shared papers)Célèste Lebbé (55 shared papers)Antoni Ribas (34 shared papers)Axel Hauschild (39 shared papers)
- Journals
- Journal of Clinical Oncology (92 papers)Annals of Oncology (38 papers)Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms (28 papers)European Journal of Cancer (26 papers)Journal of the American Academy of Dermatology (14 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Jean‐Jacques Grob
518 papers receiving 21.3k citations
Jean‐Jacques Grob's Hit Papers
Peers
Comparison fields: 5 of 176
- Oncology 10.1k
- Dermatology 2.5k
- Immunology 3.9k
- Biological Psychiatry 258
- Epidemiology 2.8k
Countries citing papers authored by Jean‐Jacques Grob
This map shows the geographic impact of Jean‐Jacques Grob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Jacques Grob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Jacques Grob more than expected).
Fields of papers citing papers by Jean‐Jacques Grob
This network shows the impact of papers produced by Jean‐Jacques Grob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Jacques Grob. The network helps show where Jean‐Jacques Grob may publish in the future.
Co-authors
The 25 scholars most cited alongside Jean‐Jacques Grob, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 551 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Hit paper breakdown → | 2009 | 939 |
| 2 | Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Hit paper breakdown → | 2000 | 938 |
| 3 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 911 |
| 4 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 788 |
| 5 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Hit paper breakdown → | 2019 | 726 |
| 6 | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Hit paper breakdown → | 2017 | 490 |
| 7 | Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies Hit paper breakdown → | 2008 | 468 |
| 8 | Melanoma Hit paper breakdown → | 2015 | 456 |
| 9 | Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 377 |
| 10 | Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial Hit paper breakdown → | 2015 | 374 |
| 11 | 2000 | 365 | |
| 12 | 1999 | 359 | |
| 13 | 2004 | 355 | |
| 14 | 2016 | 350 | |
| 15 | Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 344 |
| 16 | 2013 | 338 | |
| 17 | Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study Hit paper breakdown → | 2014 | 314 |
| 18 | 1998 | 276 | |
| 19 | 2018 | 271 | |
| 20 | 2004 | 268 |
About Jean‐Jacques Grob
Jean‐Jacques Grob is a scholar working on Oncology, Molecular Biology, Dermatology, Epidemiology and Immunology, having authored 551 papers that have together received 21.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (109 papers), Cancer Immunotherapy and Biomarkers (104 papers), CAR-T cell therapy research (97 papers), Cutaneous Melanoma Detection and Management (84 papers), Nonmelanoma Skin Cancer Studies (40 papers), Ion-surface interactions and analysis (35 papers), Immunotherapy and Immune Responses (33 papers) and Cancer and Skin Lesions (21 papers). The work is most often cited by research in Oncology (10.1k citations), Dermatology (2.5k citations), Immunology (3.9k citations), Biological Psychiatry (258 citations) and Epidemiology (2.8k citations). Jean‐Jacques Grob has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Caroline Robert, Dirk Schadendorf, Georgina V. Long, Claus Garbe, James Larkin, Célèste Lebbé, Antoni Ribas, Axel Hauschild, M.‐A. Richard and Ana Arance. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms, European Journal of Cancer and Journal of the American Academy of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.